Waxman Quoted on Synthetic Biology

14 December 2009 Nature Biotechnology News

Foley Partner and chair of the Health Care Industry Team Mark Waxman was quoted in an article titled "Engineering a new business" in the December 2009 issue of Nature Biotechnology. Waxman discusses the legal and regulatory challenges facing synthetic biology, noting that the patents involved in synthetic biology intellectual property have not been tested and a number of them make some very broad claims. He adds that a consensus needs to be reached on what ought to be regulated and how, but the problem may be difficult to solve with gene synthesis.


Related Services


Podcast Episode 24: Steve Cade, Partner
01 December 2020
Foley Career Perspectives
U.S. Companies Must Prepare to Pay Higher Wages for Specialty Occupation Foreign Workers
30 November 2020
Labor & Employment Law Perspectives
A Shield for Employers: State COVID-19 Indemnity Laws
30 November 2020
Coronavirus Resource Center:Back to Business
Federal Circuit Clarifies The “Reasonably Pertintent” Analogous Art Standard
30 November 2020
PTAB Trial Insights
HCCA San Francisco Regional Conference
04 December 2020
Virtual Conference
Webinar: Massachusetts Paid Family and Medical Leave 2021
02 December 2020
CTeL Digital Health Summit 2020
01-04 December 2020
Virtual Conference
Virtual CLE Week
Every Tuesday & Thursday from December 1 - 17 2020